Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model-Reference-Cited by-同舟云学术

Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model

Published:2009-11-23 Issue:50 Volume:106 Page:21276-21281
ISSN:0027-8424
Container-title:Proceedings of the National Academy of Sciences
language:en
Short-container-title:PNAS

Author:

Bernhardt W. M.,Gottmann U.,Doyon F.,Buchholz B.,Campean V.,Schödel J.,Reisenbuechler A.,Klaus S.,Arend M.,Flippin L.,Willam C.,Wiesener M. S.,Yard B.,Warnecke C.,Eckardt K.-U.

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

Reference49 articles.

1. Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis Awaiting Transplantation, and Recipients of a First Cadaveric Transplant

2. Long-Term Renal Allograft Survival: Have we Made Significant Progress or is it Time to Rethink our Analytic and Therapeutic Strategies?

3. Chronic Allograft Nephropathy

4. Overcoming Barriers to Long-Term Graft Survival

5. Living donor renal transplantation: recent developments and perspectives

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utilizing pathophysiological concepts of ischemia-reperfusion injury to design renoprotective strategies and therapeutic interventions for normothermic ex vivo kidney perfusion;American Journal of Transplantation;2024-07

2. Potential role of molecular hydrogen therapy on oxidative stress and redox signaling in chronic kidney disease;Biomedicine & Pharmacotherapy;2024-07

3. Hypoxia inducible factor 2α promotes tolerogenic macrophage development during cardiac transplantation through transcriptional regulation of colony stimulating factor 1 receptor;Proceedings of the National Academy of Sciences;2024-06-18

4. Hypoxia-Inducible Factor Stabilizers: an Evolving Role in Post-Transplant Anemia;Kidney International Reports;2024-06

5. Prolyl hydroxylase domain inhibitor is an effective pre-hospital pharmaceutical intervention for trauma and hemorrhagic shock;Scientific Reports;2024-02-16